A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

HAIR DISORDERS

ALOPECIA UNIVERSALIS IN A YOUNG FEMALE; SUCCESFUL COMBINATION THERAPY USING ORAL CYCLOSPORINE A AND ORAL METHYLPREDNISOLONE

S Setiawan ⁽¹⁾ - W Atmoko ⁽²⁾ - A Arimuko ⁽²⁾ - L Ashadi ⁽²⁾ - S Sukirman ⁽²⁾ - B Pendit ⁽²⁾ - I Supriyantini ⁽²⁾ - A Munawwar ⁽²⁾ - R Maria ⁽²⁾ - E Kasdjono ⁽²⁾ - D Komalasari ⁽³⁾ - K Mokoagow ⁽⁴⁾

Indonesia Central Army Hospital, Department Of Dermatology And Venerelogy, Jakarta Pusat, Indonesia ⁽¹⁾ - Indonesia Central Army Hospital, Department Of Dermatology And Venereology, Jakarta Pusat, Indonesia ⁽²⁾ - University Of Hasanuddin, Department Of Dermatology And Venereology, Makassar, Indonesia ⁽³⁾ - University Of Hasanuddin, Departement Of Dermatology And Venereology, Makassar, Indonesia ⁽⁴⁾

Background: Alopecia universalis is a condition in which patient had 100% loss of all scalp and body hair. The estimated prevalence of alopecia universalis, based on European data is 25/100,000 people.

Observation: A-28-years-old female came on July 13, 2018 with baldness on scalp and body. Hair loss started at the scalp around June 2016, and soon affected the hair on eyebrow, eyelashes, axilla, upper and fore arm, genital, and legs. July 2016, total loss on scalp and body hair. Since 2014, patient had history of chronic headache, reccurence of sprue and menstrual irregularity.

Laboratory results; ANA-IF-Speckled pattern, titer 1:320, ANA Profile negative, C3-Complement 147.9, C4-Complement 41.9, Anti TPO < 0,5. Complete hematology test, liver function, renal function, protein total, blood glucose, hormon T3, FT4, TSH and urinalysis all in normal range. Thyroid uptake 0,71%, CRP Quantitative 0,09. HBsAg non reactive. Rheumatoid factor, VDRL, TPHA were negative. Skin biopsy confirmed an alopecia on the skin.

Started July 24, 2018, we gave her cyclosporine-A tablet 3x50 mg per day concomitantly with metylprednisolone tablet 2x16 mg per day for 6 weeks. On day 21, patient reported many vellus hair on her scalp. Day-24, vellus hair on her hand. Day-39, terminal hair seen on scalp and eyebrow. Day-42, last day of medications, she had her black hair again in the scalp, eyebrow, axilla, genital and all the body. Follow up on day 81, patient still has a significant hair grow.

Key message: Alopecia universalis considered as a severe, extensive and treatment-resistant form of Alopecia Aerata, which is associated with a poor prognosis. There is still no











A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

FDA-approved treatment for AA. In this patient, an oral combination of cyclosporine-A tablet 150 mg and methylprednisolon tablet 32 mg in 6 weeks gave excellent result. Laboratory examinations were on normal range after therapy.





